EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden iD, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71092 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Mie Dyberg Skandov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptides, Obesity, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and effectiveness on body weight in adults with overweight or obesity treated in primary care. Materials and Methods This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark. The primary outcome was the relative mean change in body weight from baseline to 12‐months follow‐up in individuals who had not discontinued treatment and who had a baseline and a follow‐up weight.

Results

A total of 206 individuals were included (76% women; mean age 48 years, standard deviation (SD) 13). Mean baseline body weight was 105 kg (SD 23.8). Twelve months after treatment initiation, 38% ( n = 78) had permanently discontinued semaglutide, whilst 15% ( n = 30) had temporarily discontinued (paused) semaglutide. Approximately 48% ( n = 98) remained on treatment. Amongst these, 40% were treated with ≤ 1.0 mg/week, 30% with 1.7 mg/week and 30% with 2.4 mg/week. Relative mean body weight change after 12 months was −13.6 (95% CI −15.0 to −12.2)%.

Conclusions

Based on the experience from utilisation in a single general practise, semaglutide for weight management is frequently discontinued and titrated slower and to lower maintenance doses in real‐world clinical practise than in the approved labelling. Despite this, the observed mean weight loss for individuals who had not discontinued treatment was substantial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsGlucagon-Like PeptidesObesityOverweightSemaglutideAdultFemaleHumansMaleMiddle AgedDenmarkDose-Response Relationship, DrugRetrospective StudiesTreatment OutcomeWeight Loss

Stichwörter der Autor:innen

effectivenessprimary carereal‐world evidencesemaglutideweight management

Substanzen

Anti-Obesity AgentsGlucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.
  • Lægerne Kanaltorvet, Albertslund, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Andreas Brønden, Kristian Karstoft

Zitieren

APA

Skandov, M. D., Christensen, K. M., Dalin, D. A., Unkerskov, J., Brønden, A., Lund, M., Christensen, M. B., & Karstoft, K. (2026). Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71092

Vancouver

Skandov MD, Christensen KM, Dalin DA, Unkerskov J, Brønden A, Lund M, et al. Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71092

BibTeX
@article{Skandov2026,
  author = {Skandov, Mie Dyberg and Christensen, Katrine McLain and Dalin, Dagmar Abelone and Unkerskov, Janne and Brønden, Andreas and Lund, Marie and Christensen, Mikkel Bring and Karstoft, Kristian},
  title = {Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71092}
}
Kostenlos starten →